Eli Lilly reported Phase 3 results showing its investigational triple‑agonist retatrutide produced up to a 1.9 percentage‑point HbA1c drop and double‑digit weight loss in people with type 2 diabetes. The data—presented in topline and updated formats—mirror efficacy seen with tirzepatide (Mounjaro) on key endpoints but also include analyses that place the agent marginally behind Mounjaro on glucose lowering. Lilly’s trial included multiple dose cohorts and a 40‑week readout; company executives flagged ongoing weight‑loss trajectories and potential cardiometabolic positioning.